CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells

Wang,Jing; Xiao,Ling; Luo,Chen‑Hui; Zhou,Hui; Zeng,Liang; Zhong,Jingmin; Tang,Yan; Zhao,Xue‑Heng; Zhao,Min; Zhang,Yi

doi:10.3892/mmr.2015.3145

CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells

Authors:
- Jing Wang
- Ling Xiao
- Chen‑Hui Luo
- Hui Zhou
- Liang Zeng
- Jingmin Zhong
- Yan Tang
- Xue‑Heng Zhao
- Min Zhao
- Yi Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, P.R. China, Department of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan 410013, P.R. China, Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, P.R. China
Published online on: January 2, 2015 https://doi.org/10.3892/mmr.2015.3145
Pages: 3505-3510

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A high expression of CD44v6 has been reported in numerous malignant cancers, including stomach, prostate, lung and colon. However, the pathological role and the regulatory mechanisms of CD44v6 have yet to be elucidated. In the present study, the expression levels of CD44v6 were shown to be significantly higher in ovarian cancer tissues, as compared with adjacent normal tissues. Furthermore, the upregulated expression levels of CD44v6 were correlated with disease recurrence and poor survival in patients. The expression of CD44v6 was knocked down in the CAOV3 ovarian cell line, by transfection of a specific small hairpin RNA. The present study showed a correlation between the aggression, viability, invasion and migration of the ovarian cancer cells, with the expression of CD44v6. In addition, the expression of CD44v6 was positively correlated with the expression levels of β‑catenin and tumor growth factor‑β, which indicates that the effects of CD44v6 on ovarian cancer cell aggression may be mediated by these two signaling pathways. In conclusion, the present study provides a novel insight into the association between CD44v6 expression and ovarian cancer. CD44v6 may provide a novel target for the prognosis and treatment of ovarian cancer.

View Figures

View References

1	Naora H and Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 5:355–366. 2005. View Article : Google Scholar : PubMed/NCBI
2	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
3	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
4	Lesley J, Hyman R and Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol. 54:271–335. 1993. View Article : Google Scholar : PubMed/NCBI
5	Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI
6	Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
7	Takaishi S, Okumura T, Tu S, et al: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
8	Günthert U, Stauder R, Mayer B, Terpe HJ, Finke L and Friedrichs K: Are CD44 variant isoforms involved in human tumour progression? Cancer Surv. 24:19–42. 1995.PubMed/NCBI
9	Rall CJ and Rustgi AK: CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res. 55:1831–1835. 1995.PubMed/NCBI
10	Chen GY and Wang DR: The expression and clinical significance of CD44v in human gastric cancers. World J Gastroenterol. 6:125–127. 2000.
11	Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P and Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Gene Dev. 16:3074–3086. 2002. View Article : Google Scholar : PubMed/NCBI
12	Orian-Rousseau V, Morrison H, Matzke A, et al: Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell. 18:76–83. 2007. View Article : Google Scholar :
13	Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010. View Article : Google Scholar : PubMed/NCBI
14	Cruz MC, Pereira AL, Lopes FF, et al: Immunohistochemical expression of E-cadherin and CD44v6 in squamous cell carcinomas of the lower lip and tongue. Braz Dent J. 20:64–69. 2009. View Article : Google Scholar : PubMed/NCBI
15	Cheng XX, Wang ZC, Chen XY, et al: Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of beta-catenin. Clin Exp Metastasis. 22:85–93. 2005. View Article : Google Scholar : PubMed/NCBI
16	Todaro M, Gaggianesi M, Catalano V, et al: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar : PubMed/NCBI
17	Yingling JM, Blanchard KL and Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 3:1011–1022. 2004. View Article : Google Scholar : PubMed/NCBI
18	Siegel PM, Shu W, Cardiff RD, Muller WJ and Massagué J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA. 100:8430–8435. 2003. View Article : Google Scholar : PubMed/NCBI
19	Yao H, Ashihara E and Maekawa T: Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets. 15:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
20	Daniels DL and Weis WI: Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol. 12:364–371. 2005. View Article : Google Scholar : PubMed/NCBI
21	Yamamichi K, Uehara Y, Kitamura N, Nakane Y and Hioki K: Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer. 79:256–262. 1998. View Article : Google Scholar : PubMed/NCBI
22	Misra S, Ghatak S, Patil N, et al: Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 21:2551–2559. 2013. View Article : Google Scholar : PubMed/NCBI
23	Yanamoto S, Yamada S, Takahashi H, et al: Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence. Int J Oncol. 44:1153–1162. 2014.PubMed/NCBI
24	Wang H, Rana S, Giese N, Büchler MW and Zöller M: Tspan8, CD44v6 and alpha6 beta4 are biomarkers of migrating pancreatic cancer-initiating cells. Int J Cancer. 133:416–426. 2013. View Article : Google Scholar : PubMed/NCBI
25	Afify AM, Tate S, Durbin-Johnson B, Rocke DM and Konia T: Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers. 26:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
26	Klatte T, Seligson DB, Rao JY, et al: Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol. 183:2403–2408. 2010. View Article : Google Scholar : PubMed/NCBI
27	Crispn JC, Keenan BT, Finnell MD, et al: Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 62:1431–1437. 2010. View Article : Google Scholar
28	Shi Jm, Zhou Z, Wen Di and Li N: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer. 13:1822013. View Article : Google Scholar : PubMed/NCBI
29	Zöller M: CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 11:254–267. 2011. View Article : Google Scholar : PubMed/NCBI
30	Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar
31	Fuxe J and Karlsson MC: TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 22:455–461. 2012. View Article : Google Scholar : PubMed/NCBI
32	Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinch MS: E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 10:629–638. 1999.PubMed/NCBI
33	Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004. View Article : Google Scholar : PubMed/NCBI